Shareholders of Lexicon (LXRX +5.28%) have been on a real roller-coaster ride with this stock, as the company at one point saw its drug LX2931 beaten by an incredible placebo that reduced patient symptoms by 49%, outperforming the drug itself at 44%. Now, however, the company's drug LX1033 has a chance to make up lost ground, as it has just received a fast-track designation from the FDA in its indication to treat irritable bowel syndrome. In this video, Motley Fool health care analyst David Williamson tells us whether this is going to be a major needle-mover for Lexicon and if there are other factors to watch with this company.
1 Biotech Off to the Races
By Dave Williamson and Max Macaluso – Dec 17, 2012 at 7:06PM
NASDAQ: LXRX
Lexicon Pharmaceuticals
Market Cap
$516M
Today's Change
(5.28%) $0.07
Current Price
$1.50
Price as of November 11, 2025 at 11:05 AM ET
This company just got a fast-track designation.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid